Features
-
Biomarin limits marketing of its FVIII gene therapy, Roctavian
SAN RAFAEL, California, August 5, 2024 — Biomarin has announced that it will limit commercial, research and manufacturing programs for its factor VIII gene therapy...
-
Novel treatments in bleeding disorders: The European Haemophilia Consortium Review
CLICK HERE to access the 2024 ISSUE TWO of the periodic review of novel treatments in hemophilia and other bleeding disorders by the European Haemophilia...
-
The value in sharing our strengths
PREAMBLE In our special series of articles on the numerous committees our volunteers sit on, it is our pleasure to now present you the International...
-
Don’t ever turn your back on your dreams!
My name is Andrea, and I am the mom to my son Nicklas, who has severe hemophilia A. I am writing today to share a...
-
Opportunity to take part in a hemophilia B gene therapy trial
Hamilton, January 22, 2024 – McMaster University, in collaboration with CSL Behring, has announced a new gene therapy trial for etranacogene dezaparvovec (Hemgenix) in hemophilia...